ZNF639

Summary

ZNF639 (zinc finger protein 639, HGNC:30950) is a protein-coding gene on chromosome 3q26.33, encoding Zinc finger protein 639 (Q9UID6). Binds DNA and may function as a transcriptional repressor.

This gene encodes a member of the Kruppel-like zinc finger family of proteins. Amplification and overexpression of this gene have been observed in esophageal squamous cell carcinoma. The encoded protein has been shown to bind DNA in a sequence-specific manner and may regulate HIV-1 gene expression. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 51193 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 48 total
• MANE Select transcript: NM_001303426

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30950
Approved symbol	ZNF639
Name	zinc finger protein 639
Location	3q26.33
Locus type	gene with protein product
Status	Approved
Aliases	ANC-2H01, ZASC1
Ensembl gene	ENSG00000121864
Ensembl biotype	protein_coding
OMIM	619214
Entrez	51193

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 13 protein_coding, 1 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000326361, ENST00000466264, ENST00000466663, ENST00000481587, ENST00000483460, ENST00000484866, ENST00000491818, ENST00000494234, ENST00000496856, ENST00000621687, ENST00000908082, ENST00000908083, ENST00000908084, ENST00000908085, ENST00000971543

RefSeq mRNA: 10 — MANE Select: NM_001303426 NM_001303425, NM_001303426, NM_001375800, NM_001375802, NM_001375803, NM_001375804, NM_001375805, NM_001375806, NM_001375807, NM_016331

CCDS: CCDS3227

Canonical transcript exons

ENST00000496856 — 6 exons

Exon	Start	End
ENSE00001268779	179333269	179338583
ENSE00001268789	179328283	179328351
ENSE00001512751	179327561	179327631
ENSE00001819600	179323031	179323291
ENSE00003570719	179332989	179333123
ENSE00003661548	179329618	179329728

Expression profiles

Bgee: expression breadth ubiquitous, 264 present calls, max score 95.00.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 13.0568 / max 134.4453, expressed in 1786 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
39924	10.1699	1762
39923	2.8868	1431

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	95.00	gold quality
calcaneal tendon	UBERON:0003701	94.23	gold quality
ganglionic eminence	UBERON:0004023	93.36	gold quality
ventricular zone	UBERON:0003053	92.99	gold quality
islet of Langerhans	UBERON:0000006	92.29	gold quality
adrenal tissue	UBERON:0018303	92.08	gold quality
mucosa of stomach	UBERON:0001199	92.00	gold quality
tibial artery	UBERON:0007610	91.56	gold quality
popliteal artery	UBERON:0002250	91.55	gold quality
descending thoracic aorta	UBERON:0002345	91.39	gold quality
biceps brachii	UBERON:0001507	91.31	gold quality
aorta	UBERON:0000947	91.30	gold quality
synovial joint	UBERON:0002217	91.02	gold quality
thoracic aorta	UBERON:0001515	90.98	gold quality
caput epididymis	UBERON:0004358	90.94	gold quality
seminal vesicle	UBERON:0000998	90.91	gold quality
ascending aorta	UBERON:0001496	90.90	gold quality
right coronary artery	UBERON:0001625	90.79	gold quality
skin of hip	UBERON:0001554	90.78	gold quality
cartilage tissue	UBERON:0002418	90.73	gold quality
tendon	UBERON:0000043	90.63	gold quality
body of uterus	UBERON:0009853	90.47	gold quality
cauda epididymis	UBERON:0004360	90.41	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.41	gold quality
left uterine tube	UBERON:0001303	90.40	gold quality
endocervix	UBERON:0000458	90.39	gold quality
upper leg skin	UBERON:0004262	90.39	gold quality
lower esophagus	UBERON:0013473	90.38	gold quality
rectum	UBERON:0001052	90.37	gold quality
endometrium	UBERON:0001295	90.37	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.60

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting ZNF639, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4282	99.99	75.36	6408
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-3143	99.93	71.96	3104
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-3913-3P	99.74	66.53	938
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-494-3P	99.70	71.45	2795
HSA-MIR-30B-3P	99.70	65.76	2325

Literature-anchored findings (GeneRIF, showing 2)

• ZASC1 copy number that increased from primary to recurrent tumor suggested the importance of ZASC1 in tumor progression. The increase of ZASC1 gene copy number in recurrent tumors was associated with the consumption of betel quid in patients. (PMID:20646234)
• ZASC1 as novel regulator of HIV-1 gene expression that functions through the DNA-dependent, RNA-independent recruitment of TAT/P-TEFb to the HIV-1 promoter. (PMID:24204263)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zfp639	ENSMUSG00000027667
rattus_norvegicus	Zfp639	ENSRNOG00000043053
drosophila_melanogaster	CG14442	FBGN0029893
drosophila_melanogaster	CG14440	FBGN0029894

Paralogs (11): IKZF2 (ENSG00000030419), ZNF821 (ENSG00000102984), IKZF4 (ENSG00000123411), ZNF382 (ENSG00000161298), IKZF3 (ENSG00000161405), ZNF613 (ENSG00000176024), IKZF1 (ENSG00000185811), ZNF567 (ENSG00000189042), ZNF649 (ENSG00000198093), ZNF564 (ENSG00000249709), ZNF350 (ENSG00000256683)

Protein

Protein identifiers

Zinc finger protein 639 — Q9UID6 (reviewed: Q9UID6)

Alternative names: Zinc finger protein ANC_2H01, Zinc finger protein ZASC1

All UniProt accessions (5): C9IZP0, C9J3R1, Q9UID6, J3KR59, J3KR68

UniProt curated annotations — full annotation on UniProt →

Function. Binds DNA and may function as a transcriptional repressor.

Subunit / interactions. Interacts with CTNNA2.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

RefSeq proteins (10): NP_001290354, NP_001290355, NP_001362729, NP_001362731, NP_001362732, NP_001362733, NP_001362734, NP_001362735, NP_001362736, NP_057415 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR050527

Pfam: PF00096

UniProt features (18 total): zinc finger region 8, cross-link 4, region of interest 2, modified residue 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9UID6-F1	53.24	0.00

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 60, 88, 76, 177, 181, 226

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 133 (showing top): GOBP_HOST_MEDIATED_ACTIVATION_OF_VIRAL_TRANSCRIPTION, GOBP_GROWTH, GOBP_HOST_MEDIATED_SUPPRESSION_OF_VIRAL_TRANSCRIPTION, GOBP_MODULATION_OF_PROCESS_OF_ANOTHER_ORGANISM, chr3q26, GOBP_HOST_MEDIATED_PERTURBATION_OF_VIRAL_PROCESS, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_POSITIVE_REGULATION_OF_CELL_GROWTH, SCHAEFFER_PROSTATE_DEVELOPMENT_6HR_UP, GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_INTERACTION_WITH_HOST, GOBP_VIRAL_LIFE_CYCLE, GOBP_HOST_MEDIATED_ACTIVATION_OF_VIRAL_PROCESS, GOBP_POSITIVE_REGULATION_OF_GROWTH, MODULE_277, GOBP_CELL_GROWTH

GO Biological Process (7): regulation of transcription by RNA polymerase II (GO:0006357), positive regulation of cell growth (GO:0030307), host-mediated suppression of viral transcription (GO:0043922), host-mediated activation of viral transcription (GO:0043923), negative regulation of DNA-templated transcription (GO:0045892), positive regulation of transcription by RNA polymerase II (GO:0045944), symbiont entry into host cell (GO:0046718)

GO Molecular Function (8): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
transcription by RNA polymerase II	2
host-mediated perturbation of viral transcription	2
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
regulation of cell growth	1
cell growth	1
positive regulation of growth	1
positive regulation of cellular process	1
host-mediated suppression of viral proces	1
host-mediated activation of viral process	1
DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
regulation of transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
viral life cycle	1
symbiont entry into host	1
transcription regulatory region nucleic acid binding	1
sequence-specific double-stranded DNA binding	1
cis-regulatory region sequence-specific DNA binding	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

770 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF639	CTNNA2	P26232	569
ZNF639	ZBTB2	Q8N680	487
ZNF639	HDAC1	Q13547	417
ZNF639	ZBTB5	O15062	415
ZNF639	ZBTB25	P24278	415
ZNF639	SCRN3	Q0VDG4	414
ZNF639	K7ESF6	K7ESF6	385
ZNF639	ZNF44	P15621	385
ZNF639	ZNF629	Q9UEG4	383
ZNF639	ZNF436	Q9C0F3	383
ZNF639	ZNF569	Q5MCW4	383
ZNF639	ZNF501	Q96CX3	378
ZNF639	DCUN1D1	Q96GG9	374
ZNF639	AFF1	P51825	329
ZNF639	ANKRD54	Q6NXT1	323

IntAct

83 interactions, top by confidence:

A	B	Type	Score
HDAC1	CDK2AP1	psi-mi:“MI:0914”(association)	0.840
RBBP4	CDK2AP1	psi-mi:“MI:0914”(association)	0.790
ZNF639	PNKP	psi-mi:“MI:0915”(physical association)	0.720
PNKP	ZNF639	psi-mi:“MI:0915”(physical association)	0.720
ZBTB2	ZNF639	psi-mi:“MI:0915”(physical association)	0.670
ZBTB2	ZBTB25	psi-mi:“MI:0914”(association)	0.670
ZNF639	CTNNA2	psi-mi:“MI:0915”(physical association)	0.600
ZNF639	CTNNA2	psi-mi:“MI:0403”(colocalization)	0.600
PRPF18	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
MPP1	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
ZBTB24	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
ZNF250	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
MCRS1	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
ZNF792	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
ZNF837	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
ELAVL4	ZNF639	psi-mi:“MI:0915”(physical association)	0.560
RASSF8	CORO1A	psi-mi:“MI:0914”(association)	0.530
MBD3L1	CDK2AP1	psi-mi:“MI:0914”(association)	0.530
RIN3	ZNF639	psi-mi:“MI:0915”(physical association)	0.370
Mta1	MTA3	psi-mi:“MI:0914”(association)	0.350
Zbtb2	ENO1	psi-mi:“MI:0914”(association)	0.350

BioGRID (37): ZNF639 (Two-hybrid), ZNF639 (Affinity Capture-MS), ZNF639 (Affinity Capture-MS), ZNF639 (Two-hybrid), ZNF639 (Affinity Capture-MS), ZNF639 (Affinity Capture-MS), ZNF639 (Affinity Capture-MS), ZNF639 (Affinity Capture-MS), ZNF639 (Affinity Capture-MS), ZNF639 (Affinity Capture-MS), ZNF639 (Synthetic Lethality), ZNF639 (Two-hybrid), ZNF639 (Two-hybrid), MPP1 (Two-hybrid), ZNF837 (Two-hybrid)

ESM2 similar proteins: A0A0A6YYL3, A5PK30, A7KBS4, B3NP26, B4GBA9, B4HMH2, B4P8I0, B4QIJ9, B7ZQJ9, E1JH25, G3X9G7, H3BUK9, P10925, P18853, P20662, P98182, Q09377, Q0VCB0, Q10127, Q19203, Q290S5, Q2EI20, Q2EI21, Q4R6J4, Q5NVT2, Q5PPG4, Q5SVQ8, Q5T5D7, Q5UR86, Q65XX7, Q6IQ21, Q6NRM8, Q7JUR5, Q7K4M4, Q7Z142, Q8BIQ8, Q8C0P7, Q8IRH5, Q8NAP3, Q8T053

Diamond homologs: A5PK30, P80944, Q29419, Q5PPG4, Q99KZ6, Q9UID6, A1L2U9, A2A884, A2ANX9, A7Y7X5, A8K8V0, B1WAZ8, B1WBU4, E9PZZ1, G5EBU4, O15391, O60315, O62836, O75362, O95863, P08048, P0CS62, P0CS63, P10925, P15822, P17010, P17012, P20662, P22227, P25490, P31509, P31629, P36197, P52739, P56270, P56670, P56671, P60319, Q00899, Q00900

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 43 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
NuRD complex assembly	5	27.1×	2e-04

GO biological processes:

GO term	Partners	Fold	FDR
chromatin remodeling	5	9.3×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

745 predictions. Top by Δscore:

Variant	Effect	Δscore
3:179327632:G:GG	donor_gain	1.0000
3:179328273:C:A	acceptor_gain	1.0000
3:179328278:TTTA:T	acceptor_loss	1.0000
3:179328279:TTAG:T	acceptor_loss	1.0000
3:179328280:TA:T	acceptor_loss	1.0000
3:179328281:A:AG	acceptor_gain	1.0000
3:179328282:G:GA	acceptor_gain	1.0000
3:179328282:GAT:G	acceptor_gain	1.0000
3:179328282:GATT:G	acceptor_gain	1.0000
3:179328349:CAGG:C	donor_loss	1.0000
3:179328350:AGGTC:A	donor_loss	1.0000
3:179328352:G:A	donor_loss	1.0000
3:179328353:T:G	donor_loss	1.0000
3:179329610:A:AG	acceptor_gain	1.0000
3:179329611:T:G	acceptor_gain	1.0000
3:179329612:GTTCA:G	acceptor_loss	1.0000
3:179329614:TCAG:T	acceptor_loss	1.0000
3:179329615:CA:C	acceptor_loss	1.0000
3:179329616:A:AG	acceptor_gain	1.0000
3:179329616:AGA:A	acceptor_loss	1.0000
3:179329617:G:GG	acceptor_gain	1.0000
3:179329617:G:GT	acceptor_loss	1.0000
3:179329724:CAAAG:C	donor_loss	1.0000
3:179329725:AAAGG:A	donor_loss	1.0000
3:179329726:AAGGT:A	donor_loss	1.0000
3:179329727:AG:A	donor_loss	1.0000
3:179329728:GG:G	donor_loss	1.0000
3:179329729:G:GA	donor_loss	1.0000
3:179329730:T:A	donor_loss	1.0000
3:179332983:TTACA:T	acceptor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000181287 (3:179327958 T>C,G), RS1000412720 (3:179327198 A>G), RS1000465009 (3:179326960 TGG>T), RS1000630852 (3:179332932 A>C,G), RS1000661897 (3:179332503 A>G), RS1000678846 (3:179332911 TAA>T), RS1000788363 (3:179326785 C>A), RS1000937740 (3:179321622 T>C), RS1000944913 (3:179338262 G>A), RS1001072997 (3:179322046 T>C), RS1001326835 (3:179323213 C>A,G), RS1001519785 (3:179327869 G>A), RS1001534535 (3:179327543 T>C), RS1001619768 (3:179331516 C>A,T), RS1001652253 (3:179337733 A>G)

Disease associations

OMIM: gene MIM:619214 | disease phenotypes: MIM:158350

GenCC curated gene-disease

Mondo (1): Cowden disease (MONDO:0016063)

Orphanet (1): Cowden syndrome (Orphanet:201)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST007059_17	Response to antidepressants (symptom improvement)	3.000000e-06
GCST010273_7	Gout (normal type)	5.000000e-07

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D006223	Hamartoma Syndrome, Multiple	C04.445.435; C04.651.435; C04.700.435; C16.320.700.435

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation, affects expression	4
Cadmium Chloride	decreases expression	2
Particulate Matter	decreases expression, increases abundance, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
trichostatin A	affects expression	1
cinnamaldehyde	increases expression	1
mono-(2-ethylhexyl)phthalate	increases expression	1
sodium arsenite	decreases expression	1
K 7174	increases expression	1
jinfukang	decreases expression	1
Vorinostat	increases expression	1
Air Pollutants	decreases expression, increases abundance	1
Vehicle Emissions	increases expression, increases abundance	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1
Hydrogen Peroxide	increases expression	1
Methotrexate	increases expression	1
Methyl Methanesulfonate	decreases expression	1
Phenobarbital	affects expression	1
Quercetin	decreases expression	1
Urethane	decreases expression	1
Cyclosporine	increases expression	1
Aflatoxin M1	decreases expression	1
Copper Sulfate	decreases expression	1

Cellosaurus cell lines

2 cell lines: 1 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_HA06	K562 eGFP-ZNF639	Cancer cell line	Female
CVCL_HD35	HEK293 eGFP-ZNF639	Transformed cell line	Female

Clinical trials (associated diseases)

13 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03306446	PHASE4	UNKNOWN	Changing the coUrse of cRohn’s Disease With an Early Use of Adalimumab
NCT00971789	PHASE2	COMPLETED	Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
NCT04094675	PHASE2	COMPLETED	Sirolimus for Cowden Syndrome With Colon Polyposis
NCT00620594	PHASE1	COMPLETED	A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer
NCT01757964	PHASE1	COMPLETED	Bacteriotherapy in Pediatric Inflammatory Bowel Disease
NCT07218575	PHASE2/PHASE3	NOT_YET_RECRUITING	Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
NCT00600275	PHASE1/PHASE2	COMPLETED	A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer
NCT02856763	Not specified	COMPLETED	Predictive Factors of ANTI-TNF Response in Luminal Crohn’s Disease Complicated by Abscess
NCT03487900	Not specified	UNKNOWN	Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up
NCT03498625	Not specified	COMPLETED	Crohn’s Disease Endoscopic REmission Definition in an Objective Way
NCT03702309	Not specified	RECRUITING	Liquid Biopsy Evaluation and Repository Development at Princess Margaret
NCT06163365	Not specified	UNKNOWN	Inherited Cancer Early Diagnosis (ICED) Study
NCT06523582	Not specified	RECRUITING	Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients